TITLE

Analysis of Michigan Medicaid Costs to Treat HIV Infection

AUTHOR(S)
Solomon, David J.; Hogan, Andrew J.; Bouknight, Reynard A.; Solomon, Carolyn T.
PUB. DATE
September 1989
SOURCE
Public Health Reports;Sep/Oct89, Vol. 104 Issue 5, p416
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To obtain better understanding of the nature and cost of health care related to human immunodeficiency virus (HIV) infection, medical payment records were analyzed for 204 men, women, and children older than 60 months who had indications of HIV infection. The records were those of Michigan Medicaid, the General Assistance Medical Program, and the Resident County Hospitalization Program, with service dates on or after January 1, 1984, and which were processed by November 30, 1987. Patient payment records were coded according to whether the patient's condition was considered to be pre-HIV, HIV unrelated, possibly HIV related, or HIV related. Average monthly payments were found to be $150 for pre-HIV patient payment records, $114 for those HIV unrelated, $57 for those possibly related, and $1,213 for those related to HIV infection. HI V-related monthly payments rose from about $1,500 per month in the period 3 months prior to the patient's death to more than $8,000 in the last month of life. Men were found to have twice as many claims as women, and men's claims cost about three times as much. A higher percentage of women than men (91 percent versus 37 percent) received pre-HIV paid services, indicating a higher percentage of women were at least initially receiving Medicaid for reasons other than an HIV-related disability. Diagnostic categories that accounted for the bulk of the HI V-related health care utilization included infectious and parasitic diseases, acquired immunodeficiency syndrome, diseases of the respiratory system, and non-HI V-specific immunity disorders. Inpatient hospitalization accounted for more than 75 percent of the payments, followed by physician costs (11 percent), pharmacy costs (5 percent), and outpatient costs (3 percent). A total of 45, or about 22 percent of the recipients, received zidovudine (AZT) prescriptions at an average monthly cost of $404.
ACCESSION #
24449194

 

Related Articles

  • Budget Impact of Medicaid Section 1115 Demonstrations for Early HIV Treatment. Schackman, Bruce R.; Freedberg, Kenneth A.; Goldie, Sue J.; Weinstein, Milton C.; Swartz, Katherine // Health Care Financing Review;Summer2005, Vol. 26 Issue 4, p67 

    A state-transition model of HIV disease was used to project the costs to Medicaid, Medicare, and AIDS Drug Assistance Programs of proposed Section 1115 Medicaid demonstration projects for the early treatment of HIV-infected patients in Georgia and Massachusetts. Neither demonstration project was...

  • Coping with the cost burdens of illness: Combining qualitative and quantitative methods in longitudinal, household research. Goudge, Jane; Gumede, Tebogo; Gilson, Lucy; Russell, Steve; Tollman, Stephen M.; Mills, Anne // Scandinavian Journal of Public Health;May2007 Supplement 69, Vol. 35 Issue s69, p181 

    Over the last 10-15 years, poor African households have had to cope with the burden of increased levels of chronic illness such as HIV/AIDS. How do these households cope with the cost burdens of ill health and healthcare, and has this burden further impoverished them? What policy responses might...

  • State AIDS Drug Assistance Programs Continue to Face Difficult Funding Challenges; 11 States Close Enrollment, 9 Have Waiting Lists to Receive HIV Drugs; Wide Variation in Access to HIV...  // Ascribe Newswire: Medicine;5/20/2004, p165 

    Despite a 9 percent increase in the overall AIDS Drug Assistance Programs (ADAPs) budget in the U.S. between fiscal year 2002 and 2003, an increasing number of people living longer with HIV/AIDS, the rising costs of HIV medications, and continuing fiscal pressures at the Federal and state levels...

  • Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. Freedberg, K.A.; Paltiel, A.D. // PharmacoEconomics;1998, Vol. 14 Issue 2, p165 

    Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an...

  • HIV patients live years after diagnosis.  // Gay & Lesbian Times;11/16/2006, Issue 986, p28 

    The article reports on the results of a research which show that an American diagnosed with the AIDS virus can expect to live for about 24 years on average. The research also shows that the cost of health care throughout those decades is more than $600,000. Bruce Schackman is the lead author of...

  • Financing Health Care for Persons with HIV Infection: Guidelines for State Action. Fox, Daniel M. // American Journal of Law & Medicine;1990, Vol. 16 Issue 1/2, p223 

    Promises of confidentiality of HIV-related medical records and protection from discrimination based on HIV seropositivity are two of the legislative inducements state governments have offered to encourage voluntary HIV testing. Yet neither can be granted without impact on others whose interests...

  • The Impact of Comprehensive Case Management on HIV Client Outcomes. Brennan-Ing, Mark; Seidel, Liz; Rodgers, Leslie; Ernst, Jerome; Wirth, Doug; Tietz, Daniel; Morretti, Antonio; Karpiak, Stephen E. // PLoS ONE;2/5/2016, Vol. 11 Issue 2, p1 

    In 1990, New York State instituted Comprehensive Medicaid Case Management, also known as Target Case Management (TCM), for people dealing with multiple comorbid conditions, including HIV. The goal of TCM is to assist clients in navigating the health care system to increase care engagement and...

  • Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid. Kahn, James G.; Haile, Brian; Kates, Jennifer; Chang, Sophia // American Journal of Public Health;Sep2001, Vol. 91 Issue 9, p1464 

    Conclusions. Expansion of the Medicaid eligibility to increase access to antiretroviral therapy would have substantial health benefits at affordable costs. (Am J Public Health. 2001;91:1464-1473)

  • Health Economics in HIV Disease: A Review of the European Literature. Youle, M.; Trueman, P.; Simpson, K. // PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1 

    The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics